Clinical & Genetic Investigation of the Association Between Primary

Status Completed

Clinical Trial Summary

Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A higher prevalence of thyroid nodules and non-toxic multinodular goiter was described in patients with PA compared to those with essential hypertension (EH). A single study showed an association between PA and papillary thyroid cancer (PTC), but without a paired control group. Objective: To assess PA prevalence in a transversal cohort of patients with PTC and EH compared to a paired control group with HT.

Clinical Trial Description

Primary aldosteronism (PA) is the most frequent cause of endocrine hypertension, with an estimated prevalence of 20% among individuals with resistant hypertension. PA is associated with an increased risk of malignancy, probably due to aldosterone effects in promoting cell proliferation. Recently, a high prevalence of PA was demonstrated in patients with essential hypertension (EH) and papillary thyroid cancer (PTC), similarly to the prevalence of PA among individuals with resistant EH. In addition, abnormalities in thyroid ultrasound (non-toxic multinodular goiter) are more common in PA patients when compared to controls. Despite of this initial evidence, the link between PA and PTC remains to be elucidated. Then, the aim of this study is to investigate the clinical and genetic aspects of the association between PA and PTC. The specific aims are: 1) To evaluate the prevalence of PA in a transversal cohort of patients with EH and PCT; 2) To investigate thyroid ultrasonography abnormalities in PA patients; 3) To perform exome sequencing (blood DNA) in patients with PA and PTC paired with tumor tissue; and 4) To conduct functional studies of the novel genetic variants identified by exome sequencing. To achieve this goal, the investigators will employ the following techniques: next-generation sequencing, bioinformatic analysis, real-time PCR and immunohistochemistry. In this project, the investigators expect to establish the prevalence of PA among patients with EH and PTC, and to identify new genetic targets involved in the association between PA in PTC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06068101
Study type	Observational
Source	Instituto do Cancer do Estado de São Paulo
Contact
Status	Completed
Phase
Start date	March 1, 2019
Completion date	August 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02885662` - Study of CS-3150 in Patients With Primary Aldosteronism	N/A
Withdrawn	`NCT02096939` - Microvascular Function in Primary Aldosteronism	N/A
Completed	`NCT01728493` - Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment	N/A
Recruiting	`NCT06228677` - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting	`NCT06047912` - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting	`NCT04991961` - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting	`NCT05405101` - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA	N/A
Recruiting	`NCT05501080` - The Effect of SAAE on Ventricular Remodeling in PA Patients	N/A
Recruiting	`NCT05973604` - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting	`NCT05826080` - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed	`NCT04179019` - Calcium Channel Blockade in Primary Aldosteronism	Phase 2
Completed	`NCT03500120` - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting	`NCT04213963` - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed	`NCT05435703` - Renal Cysts and Primary Aldosteronism
Recruiting	`NCT02945904` - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation	`NCT02257450` - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study	N/A
Recruiting	`NCT05561361` - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed	`NCT03398785` - Adrenal Artery Ablation Treats Primary Aldosteronism	Phase 3
Recruiting	`NCT03224312` - Chongqing Primary Aldosteronism Study
Recruiting	`NCT04428827` - Outcome of Patients With Primary Aldosteronism

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms